The immunosuppressive activity of ara-C (cytarabine) and derivatives.
D000276:Adjuvants, Immunologic; D000818:Animals; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy; D006224:Cricetinae; D003561:Cytarabine / Q000494:pharmacology*; D004285:Dogs; D004357:Drug Synergism; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology; D004927:Escherichia coli Infections / Q000276:immunology; D006084:Graft Rejection; D006087:Graft vs Host Reaction; D006168:Guinea Pigs; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D051379:Mice; D009369:Neoplasms / Q000276:immunology; D011817:Rabbits; D051381:Rats; D016038:Skin Transplantation; D014184:Transplantation, Homologous
D000276:Adjuvants, Immunologic; D000961:Antilymphocyte Serum; D003561:Cytarabine